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DOI 10.1016/j.chembiol.2012.06.006Every six hours for 17 years, Natalie
Stack, 21, gulped down cysteamine,
a noxious medication to rid her body of
excess cystine. Hourly, she applied
eyedrops to protect her vision. Natalie
was born with cystinosis, a rare genetic
lysosomal storage disease in which
cystine, an amino acid, accumulates,
leading to organ, brain, and eye damage
and eventual kidney failure. About 500
people in the US, mostly children, have
cystinosis, with perhaps 2000 total
sufferers worldwide.
On her 12th birthday, Natalie’s mother,
Nancy, took her out to a restaurant and‘‘Broadly, there are more than 6000 rare diseases and 400 FDA-
approved molecules that have received orphan disease designa-
tion.’’ — John McKew, Ph.D.asked her what her birthday wish was.
‘‘To have my disease go away forever,’’
Natalie scribbled on a napkin. ‘‘Six weeks
later, we had our first fundraiser,’’
recounts Nancy. Over the past ten years,
the Cystinosis Research Foundation
(CRF) (http://www.natalieswish.org/) has
raised almost $20 million for research,
created a scientific review board, hosted
biennial international research sympo-
siums, and attracted NIH grants. Cystino-
sis families working with CRF raised $1.8
million as well. The foundation estab-
lished the first patient registry (https://
cystinosis.patientcrossroads.org/) includ-
ing 370 patients from 32 countries, which
is now to be a part of the NIH Global
Rare Diseases Patient Registry and Data
Repository (GRDR).
CRF sponsored bench and clinical re-
search trials that led to an enteric-coated,
delayed-release form of cysteamine (EC
cysteamine) that can be taken every 12 hr
and is easier on small tummies. Working
with the CRF to expedite clinical trials,
Novato, CA, based Raptor Pharmaceu-ticals (http://www.raptorpharma.com/)
reformulated the drug as a microbead
capsule called RP103.
Natalie and the other children who
volunteered for studies were granted
compassionate use status for EC cyste-
amine until it receives FDA approval. The
CRF is sponsoring research into de-
layed-release eye drops to remove crystal
accumulation. A long-term goal is gene
therapy. ‘‘Rare disease research relies
on private donations—the only hope
we have is to support the research
ourselves,’’ said Nancy Stack. ‘‘It is our
daughter whose life is at stake. There isno cure, but we have made tremendous
research progress.’’
The NIH Pitches In
This DIY approach to drug discovery is
commonplace in the rare disease world,
where patients and their families have
few alternatives. Pharmaceutical compa-
nies have shied away from rare and ne-
glected diseases because of their limited
commercial potential. But as blockbuster
drugs succumb to generic competition,
this is changing. The NIH is launching
new translational research to speed the
process of getting drugs to people, spear-
heading initiatives to repurpose discarded
drugs from industry (http://www.ncats.
nih.gov/research/reengineering/rescue-
repurpose/therapeutic-uses/therapeutic-
uses.html/) as well as investing in
knowledge infrastructure such as patient
registries and natural history databases.
Concurrently, the number of publicly
available genomic databases is exploding
because of cheaper gene chips, open
access policies, advanced computingChemistry & Biology 19, June 22, 2012techniques, and high-throughput screen-
ing to map human variants, enabling
researchers to connect seemingly unre-
lated points of information.
‘‘Broadly, there are more than 6000 rare
diseases and 400 FDA-approved mole-
cules that have received orphan disease
designation,’’ said John McKew, Ph.D.,
chief of Therapeutics Development
Branch at the NIH’s Therapeutics for
Rare and Neglected Diseases (TRND).
‘‘Those 400 molecules address just 250
rare disease indications, which leaves an
awful lot of new diseases, each with
a different clinical presentation, genotype,
and phenotype correlation.’’
About 80% of rare diseases are genetic
and affect mostly children. The US
defines a rare disease as having a preva-
lence of fewer than 200,000 people. (The
FDA counts rare disease prevalence, not
incidence.) In Europe, a rare disease is
defined as affecting less than 1 in 2,000
people. About 25–30 million people in
the US and 350 million people worldwide
suffer from a rare disease.
The NIH launched TRND in 2009, incor-
porating it in 2011 into its new National
Center for Advancing Translational
Sciences (NCATS) Office of Preclinical
Innovation. TRND shepherds promising
preclinical compounds into early clinical
development. Program participants get
access to a wealth of NIH resources
including medicinal chemistry optimiza-
tion; development of biomarkers, assays,
and formulations; toxicology studies; and
guidance with early stage clinical trials
and regulatory and IND filing.
The 2002 Orphan Drug Act, with its
waived PDUFA (Prescription Drug User
Fee Act), streamlined clinical trial re-
quirements, and seven year patent exclu-
sivity opened the door for a number of
biotechnology companies to profitably
develop treatments for orphan diseases.
McKew cited the approval of Ivacaftor
(Kalydeco), developed by Vertex Phar-
maceuticals and the Cystic Fibrosisª2012 Elsevier Ltd All rights reserved 657
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fibrosis patients—about 1200 people—
with a particular genetic mutation. ‘‘It is
a model of venture philanthropy working
with a private biotech company,’’ McKew
said. Vertex was able to price Kalydeco at
$200,000 annually because it provided
transformational care not otherwise
available.
‘‘We reach out to researchers in the rare
and neglected tropical disease area and
work with them to generate the data
they need to advance their projects,’’
said McKew. Last year, TRND ran two
rounds of solicitations and accepted 10
principal investigators out of 120 appli-
cants. ‘‘Our criteria are based on the
scientific validity of the target,’’ said
McKew. ‘‘Our scoring matrix includes
target validation, strength of the current
data package, feasibility for first in human
studies, and the likelihood of external
adoption. The end goal is for a compound
to be sufficiently derisked after a TRND
collaboration that it can be picked up by
venture philanthropy or corporations.’’
Rare in the US, a Scourge
in the Developing World
One TRND candidate is Aes-103, an
antisickling agent being developed by
Massachusetts startup AesRx, LLC,
(http://www.aesrx.com/). Aes-103 just
commenced phase 1/2a clinical trials in
patients with sickle cell disease. The
AesRx/NIH collaboration also involved
the National Heart, Lung, and Blood Insti-
tute (NHLBI).
Sickle cell disease is an inherited
disorder that distends red blood cells
into sickle shapes, impairing their ability
to carry oxygen. The misshapen cells
can clog blood vessels, causing bouts of
pain, organ damage, and infection. There
is currently no cure, but symptoms are
treated with blood transfusions and bone
marrow stem cell transplants. The genetic
mutation for sickle cell, although protec-
tive against malaria, affects 70,000
people in the US, but millions in Africa,
India, and South America.
Licensed from Virginia Commonwealth
University, Aes-103 (5-hydroxymethyl-2-
furfural) is an orally bioavailable small
molecule compound that binds specifi-
cally to sickle hemoglobin (HbS). It
increases the ability of sickle red blood
cells to bind oxygen, reducing the number
of cells that can sickle.658 Chemistry & Biology 19, June 22, 2012 ª‘‘What has changed over the past years
is that there is less private sector venture
capital doing translational research,’’
said Stephen Seiler, CEO of AesRx. Ac-
cording to Seiler, venture investment falls
short of the point five years down the
pipeline when biotech companies can
go public or pharmaceutical companies
acquire early stage compounds. It is
hard to recruit patients for trials and end
points are fewer or not necessarily
apparent. ‘‘TRND will enable us to begin
to bridge the biotech valley of death,
from preclinical to IND,’’ Seiler said.
AesRx is looking for marketing partners
among the nonprofits in the developing
world. ‘‘Once we achieve proof of
concept, we believe that sector will be
engaged in the program and take it the
rest of the way,’’ said Seiler. ‘‘There is
a huge market in Africa—12 million. The
vast majority of patients will not live to
age five. In India—1 million. How this
drug is made successful at an appropriate
price range, look at HIV.’’ (Seiler is refer-
ring to HIV drug companies accepting
a lower price in the poorer regions of the
world than in the developed areas.)
What would AesRx have done other-
wise? ‘‘It would have been very chal-
lenging, a reasonable possibility that it
would not have happened without TRND
and NHLBI,’’ said Seiler. But the land-
scape is changing. ‘‘In the last 24 months,
the larger companies are increasingly
becoming aware that you can make a
living doing this,’’ said Seiler.
Connecting Data Points
and Patients
‘‘The interesting point, if you give industry
enough basic research, a drug will be
developed,’’ said Rob Derham, founder of
CheckOrphan (http://www.checkorphan.
org/), a news platform for orphan disease
patients. ‘‘In the past, people have used
the excuse of return on investment. True,
they have to charge more. The real
problem is lack of basic research.’’
The orphan disease world is atomized
and its foundations tend to be disease
specific. Umbrella organizations such as
the National Organization for Rare Disor-
ders (NORD) (http://www.rarediseases.
org/) and the European Organization
for Rare Diseases (EURORDIS) (http://
www.eurordis.org/) try to foster connec-
tions among members through social
media sites and events like Rare Disease2012 Elsevier Ltd All rights reservedDay, where everybody wears jeans
(alluding to DNA).
But the NIH wants to take a more
rigorous data-driven approach to identi-
fying patients and collecting genetic test
information and clinical status markers
for rare diseases. In a two year pilot
program to aggregate disparate patient
registries, the NIH Office of Rare Disease
Research (ORDR) is constructing the
Rare Diseases Patient Registry and Data
Repository. The NIH will also collect infor-
mation on the natural history of rare
diseases to determine likely endpoints
for trials. Companies already maintain
proprietary product registries, but they
may be mandated to supply postapproval
market surveillance information to the
FDA—particularly important in orphan
drug trials with reduced patient numbers.
The patient registries are being built
and operated by San Mateo, CA,
based Patient Crossroads (https://www.
innolyst.com/) in partnership with Med-
scape, WebMD, and Childrens’ Hospital
of Philadelphia. Initially, PatientCross-
roads will collect and integrate into the
GRDR deidentified data from the 15 new
registries the NIH is funding through the
pilot period, as well as the contents of
19 existing external registries. The goal
is to amass data on 200 rare diseases by
the end of the pilot period.
‘‘You can’t run a report out of a social
network,’’ said PatientCrossroads CEO
Kyle Brown. According to Brown, every-
body wants to ‘‘own’’ the patient and
has different motivations for amassing
information, but they don’t necessarily
want to share it. PatientCrossroads will
partner with foundations as ‘‘trusted gate-
keepers’’ to collect patient information
and curate the collected, deidentified
data, eventually connecting it to tissue
banks. Patients can opt in or out. ‘‘We
are trying to create a standardized
platform that makes data available, so
anyone can use it,’’ said Brown. ‘‘A global
rare disease registry to facilitate research
and clinical trials. In some ways, it is like
open sourcing. The real nut of this is if
we can start looking pan-disease.’’
Brown cites a tiny foundation for a
rare autism spectrum condition called
Phelan-McDermid Syndrome (PMS).
Research showed the SHANK3 gene,
located on chromosome 22 is asso-
ciated with the neurobehavioral symp-
toms of PMS patients. But SHANK3 was
Chemistry & Biology
Innovationsalso implicated in Alzheimers disease
(Grabrucker et al., 2011). ‘‘Suddenly
pharma companies were coming out
of the woodwork,’’ said Brown. ‘‘Four
years ago, people thought I was smoking
something,’’ said Brown. ‘‘Now they aregetting it. If we share, we can help people
faster.’’
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